Kairos
Messages : 42
Enregistré le : sam. sept. 21, 2019 9:42 am

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non

mer. févr. 26, 2020 5:34 pm

www.thelancet.com/haematology Vol 7 March 2020

Summary
The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment.

« Implications of all the available evidence Taken together with pre-existing evidence, these findings suggest that ropeginterferon alfa-2b can be considered as first-line cytoreductive therapy instead of hydroxyurea and should therefore change treatment algorithms for polycythaemia vera »


Retourner vers « Maladie de Vaquez »

Connexion  •  S’enregistrer